title: Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis.
abstract: To establish incidence and risk factors for development of second malignant neoplasms after high-dose chemo/radiotherapy (HDT) and autologous hematopoietic stem cell transplantation (AHSCT), the case files of 800 consecutive patients who underwent AHSCT at our institution between June 1982 and December 2000 were reviewed. In all, 26 patients developed 29 second malignancies (nine myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML), 16 solid tumors and four lymphoproliferative disorders (LPDs)) for a 15-year cumulative incidence of 11% (95% confidence interval (CI), 5-18%). These second tumors occurred at a median of 68 (range 1.5-177) months following AHSCT. The relative risk (RR) compared to the general population of developing a second malignancy following AHSCT was 3.3 (CI 2.2-4.7) P<0.001. The RR of developing MDS/AML, LPD and a solid tumor was 47.2 (CI 21.5-89.5) P<0.001, 8.1 (2.2-20.7) P=0.002 and 1.98 (1.1-3.2) P=0.009, respectively. In multivariate analysis, age >or=35 years at the time of AHSCT (P=0.001) and an interval from diagnosis to AHSCT >or=36 months (P=0.03) were associated with a greater risk of developing a second malignancy. Patients who have undergone HDT and AHSCT are at significant risk for developing a second malignancy and should receive indefinite follow-up.
authors.affiliation: Division of Hematology, British Columbia Cancer Agency and Vancouver General Hospital, Vancouver, British Columbia, Canada. dforrest@bccancer.bc.ca
authors.forename: D L
authors.initials: DL
authors.lastname: Forrest
authors.forename: T J
authors.initials: TJ
authors.lastname: Nevill
authors.forename: S C
authors.initials: SC
authors.lastname: Naiman
authors.forename: A
authors.initials: A
authors.lastname: Le
authors.forename: D A
authors.initials: DA
authors.lastname: Brockington
authors.forename: M J
authors.initials: MJ
authors.lastname: Barnett
authors.forename: J C
authors.initials: JC
authors.lastname: Lavoie
authors.forename: S H
authors.initials: SH
authors.lastname: Nantel
authors.forename: K W
authors.initials: KW
authors.lastname: Song
authors.forename: J D
authors.initials: JD
authors.lastname: Shepherd
authors.forename: H J
authors.initials: HJ
authors.lastname: Sutherland
authors.forename: C L
authors.initials: CL
authors.lastname: Toze
authors.forename: J H
authors.initials: JH
authors.lastname: Davis
authors.forename: D E
authors.initials: DE
authors.lastname: Hogge
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000209:etiology; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000145:classification / Q000209:etiology*; D011336:Probability; D012189:Retrospective Studies; D012307:Risk Factors; D014182:Transplantation, Autologous